// Yihua Liu 1, 2 , Huiting Fan 1 , Ying Zhang 1 , Yong Yang 3 and Hongsheng Lin 1 1 Department of Oncology, Guang'anmen Hospital, Affiliated to China Academy of Chinese Medical Sciences, Beijing, 100053, China 2 Beijing University of Chinese Medicine, Beijing, 100029, China 3 Department of Oncology, Beijing Hospital of Traditional Chinese Medicine, Beijing, 100010, China Correspondence to: Hongsheng Lin, email: drlinhongsheng@126.com Keywords: nab-paclitaxel; taxanes; peripheral neuropathy; hematological toxicities; meta-analysis Received: August 19, 2017 Accepted: November 13, 2017 Published: January 02, 2018 ABSTRACT Background: Nab-paclitaxel represents a promising therapeutic approach being developed. There are concerns about the increased risk of toxicities with nab-paclitaxel. This study performed an up-to-date meta-analysis of all phase II and III prospective clinical trials of nab-paclitaxel to quantify the increased risk of peripheral neuropathy (PN) and hematological toxicities for cancer patients. Materials and Methods: We carried out a systematic literature search of electronic databases and proceedings of oncologic meetings published before May 2017. Eligibility criteria included phase II and III trials of nab-paclitaxel reported adequate safety profiles. Data were extracted from each study and pooled to determine the overall incidence, relative risks (RRs) and 95% confidence intervals (CIs). Results: A total of 7,491 patients with a variety of solid tumors from 30 clinical trials were identified. The results revealed that the incidences of nab-paclitaxel associated all-grade and high-grade hematological toxicities and PN were, neutropenia: 62.5% and 27.2%; leukopenia: 63.9% and 17.2%, anemia: 56.5% and 6.2%, thrombocytopenia: 11.4% and 3.3%, PN: 67.0% and 13.4%, respectively. Compared with taxanes, nab-paclitaxel use did not significantly increase the risk of hematological toxicities and PN. However, this association varied significantly with tumor types and controlled therapies. Conclusions: Nab-paclitaxel associated hematological toxicities are modest and manageable comparable with taxanes, while clinicians should be cautious with PN when adding nab-paclitaxel to the therapies for breast cancer patients.